We are currently upgrading our website. Please bear with us if you are experiencing any loading issues.
The inaugural Value-Based Market Access (VBMA) Symposium revolves around the theme “The Evolving Health Technology Assessment Landscape for Medical Devices and Diagnostics”. We will bring together key stakeholders in the healthcare ecosystem to advocate for innovative, value-based market access – including and not limited to pricing, procurement, value assessment and reimbursement.
With a unified voice at the VBMA Symposium in June 2022, MedTech companies will speak with visibility, credibility and partnerships to the wider healthcare ecosystem. We seek to showcase MedTech sector’s capability and commitment to partner governments in policy shaping, impact assessment and implementation of value-based healthcare in the Asia-Pacific region.
The VBMA symposium will leverage technical expertise, real-world operating experience and networks from the extensive community of government affairs and market access industry professionals across over 15 APAC markets from more than 40 companies in the medical device and diagnostics sector.
Facilitate collaboration between government, non-government and industry stakeholders to improve patient access to medical technologies in value-based healthcare
Promote smoother and well-defined post-approval value-based access pathways
Facilitate best practice sharing on value-based pricing, procurement and reimbursement models amongst economies across the region
From Cost-Based Healthcare to Value-Based Health Systems
Value-Based Assessment for Innovative and Enhanced Medical Devices
Value of Real-World Evidence for Medical Device Reimbursement and Performance-Based Funding
Value Assessment for Diagnostics – Is A New Paradigm Needed?
Value Assessment of Innovative Technologies under Diagnosis-Related Group (DRG) Funding Reforms
Value assessment of innovative technologies under DRG – A Case Study from Germany
Current Practices in China:
Value assessment pilots in Beijing
Current Practices in China:
Value assessment pilots in Wuhan
Experiences and learnings in the current DRG reform
Setting an appropriate framework of MedTech innovation in DRG reform for the future
Australia & Korea
Value-Based Healthcare (VBHC) in Australia and Korea’s MedTech Sector: Are We On The Right Track?
Providing Quality Healthcare in Universal Health Coverage (UHC) through Value-Based Pricing
Shakilla Shahjihan is Divisional Vice President, Government Affairs at Abbott based in Singapore. She and her team members across strategic markets in the region lead external stakeholder engagement to drive business priorities.
Prior to joining Abbott, Shakilla held various positions in sales, marketing and corporate affairs at Monsanto, Boston Scientific and Merch Sharp and Dohme.
Shakilla chairs the Government Affairs Committee of APACMED (Asia Pacific Medical Technology Association), working together with the Secretariat and GAMA leadership team to advocate on issues and bring meaningful programmes for APACMED’s members. She is also an active Management Committee member at the Asia Pacific Infant and Young Child Nutrition Association. She sits on the Board of the American Chamber of Commerce, Singapore.
Shakilla holds a Bachelor of Science degree and an Executive MBA from the National University of Singapore.
Shakilla’s passion is to help young women discover their full potential. She is a mentor at the National University of Singapore. She also enjoys discovering new places, the arts and yoga.
Dr Rifat Atun is Professor of Global Health Systems at Harvard University and the Faculty Chair for the Harvard Ministerial Leadership Program. His research has two major strands. The first examines health systems performance and how design and implementation of health systems reforms impact on outcomes. The second strand of research explores adoption and diffusion of innovations in health systems, and innovative financing in global health.
Professor Atun has published more than 400 papers in leading journals and has been a commissioner in 12 Lancet Commissions and was a co-author and member of the Advisory Committee for the Editors for Disease Control Priorities (DCP).
Prof. Atun has worked with more than 30 governments globally and with the World Bank, World Health Organization, and the UK Department for International Development (DfID) to design, implement and evaluate health system reform initiatives. Prof. Atun was the Founding Director of the MSc in International Health Management, BSc in Management and Medical Science, and Founding Co-Director of the Masters in Public Health (MPH) Programmes at Imperial College. He has been a founding director and is an active investor in health technology companies operating in areas of digital health, health service delivery, medical diagnostics and biotechnology. He also advises new ventures operating in these areas.
Prof. Atun chaired the WHO Task Force on Health Systems and Tuberculosis Control and in 2009-12, he was the Chair of the STOP TB Partnership Coordinating Board. He is a member of The Longitude Prize Committee, the largest science prize in the world. He is currently serving as a Member of the WHO Regional Director’s Advisory Council on Innovation for Noncommunicable Diseases (the NCD Advisory Council).
Feras Mahdi is the Head of MedTech, Asia Pacific Regional Headquarters and Southeast Asia at IQVIA. In this role he is responsible for IQVIA’s strategy and commercial consulting services provided across the MedTech space. He is passionate about data science and is focused on driving deep analytics solutions for complex client problems.
Prior to joining IQVIA, Feras was the APAC regional director for Medtronic’s Gastrointestinal business unit, where he drove strategic growth with key product launches including first-of-its-kind AI-powered diagnostic devices. Feras was also Director at GE Healthcare Partners where he led award winning large scale transformation projects in both the public and private healthcare provider sectors. In addition, Feras co-founded CamStent Ltd, a UK based medical device company that manufactures bacteria resistant catheters.
Feras is a strong advocate for inclusion and disability rights, serving as Chair and Board member of Empowerment Through Integration, an international non governmental organisation working with the visually impaired.
Feras holds a Master’s degree in BioScience Enterprise from the Judge Business School, University of Cambridge as well as a Doctor of Medicine and Bachelor of Science in Biology from the American University of Beirut. He also completed a residency in Internal Medicine at the university.
Virginia is our Asia Pacific HEMA Director at Boston Scientific. She leads a team of access professionals in developing strategies and evidence to support patient access across the region.
Virginia has 15 years’ experience in health economics and market access for pharmaceuticals and medical
devices for both Government and industry. Prior to Boston Scientific Virginia assessed medicines for public-sector reimbursement for both the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia and PHARMAC, the New Zealand’s Pharmaceutical Management Agency. She has worked across a broad range of
therapeutic areas including oncology, infection, auto-immune diseases, ophthalmology, smoking cessation, mental health, cardiovascular and renal disease.
Vice President, Global Head Real World Evidence, IQVIA MedTech
Working with MedTech companies around the world to design & deliver solutions that translate evolving methodological real-world research standards and real-world data generation methods into feasible strategies to meet the needs of regulators, payers, providers & patients.
Ms. Bulliard has over 25 years’ experience in real-world evidence generation, patient registries, safety surveillance programs, health economics & outcomes research and other specialized real-world programs. She has an extensive global portfolio, specializing in medical device & diagnostics studies. Ms. Bulliard is a member of IQVIA’s MedTech Center of Excellence representing the domain of real-world evidence. She has previously held senior positions in the field of real-world research in medical device and biotech companies.
Areas of expertise
A subject matter expert in RWE medical device, diagnostic and digital health studies with a robust knowledge of the current and evolving clinical, regulatory, scientific and commercial medtech landscape, she seeks to generate product value by leveraging the most effective, innovative and compelling strategies within the marketplace.
Bachelor of Science in Nursing, BScN, RN, Dr Steevens Hospital / Trinity College Dublin Ireland,
Vibhav Garg serves as the Director-Govt Affairs Strategy for India, India HUB & ASEAN and Head-Govt Business, India & India HUB for Boston Scientific. He has extensive global experience of more than 2 decades in the areas of Policy Advocacy, Brand Management, Regulatory & Compliance, Public Affairs, Corporate Communications, Crisis Management and has been engaging with state and federal government of India, South Asian, South East Asian and other developing countries for various strategic healthcare initiatives and policy discussions with concerned stakeholders.
Prior to rejoining Boston Scientific , Vibhav held various strategic positions with US & India headquartered organizations like GE Healthcare as Vice President-Health Policy & Govt Affairs, Boston Scientific India as Associate Director-Health Economics & Govt Affairs; Confederation of India Industry, the apex industry body in India, as Head of Life Sciences & Healthcare; Mascon Global Limited, a boutique management and IT consulting organization, spearheaded their healthcare and life sciences initiatives in India and US as well; and Brainwave Biosolutions Ltd where he lead the life sciences and healthcare practice of the organization. Most recently he was associated with Indian Pharmaceutical Alliance, the pharma trade association, as Associate Secretary General.
He is a pharmacy graduate from GJU, Hissar followed by Master of Engineering in Biotechnology from BITS, Pilani and Advanced Diploma in Business Administration from All India Management Association. He is currently pursuing Doctorate in Business Administration & General Management with specialization in Health Policy. His thoughts, views and research have been published in various peer reviewed journals and magazines and he has delivered many national and international invited lectures. Vibhav is currently Industry Co-Chair in Asian Harmonization Working party (AHWP) representing Indian Medical Device Industry and also Chair of India GAMA Center of Excellence (CoE) at APACMed (Asia Pacific Medical Technology Association). Additionally, he is the Chair of Policy subgroup of CII (Confederation of Indian Industry), Co-Chair of FICCI Medical Device Policy Committee and Co-Lead for Value Based Procurement working group of APACMed India CoE. He was also the Vice Chair of AdvaMed (Advanced Medical Technology Association) in India and currently leads multiple other committees in trade associations like CII, FICCI, AmCham, USISPF, MTaI and other industry associations. He has also been advising various departments in different ministries of Government of India like Department of IT, Health, and Biotechnology in various capacities.
Mikki has over 15 years of experience in the life science and diagnostic industry living and working across multiple geographies. She is currently the Director of Health Policy & External Affairs for Roche Diagnostic International where she is active in various industry associations.
This includes the APACMED IVD working group where she has actively contributed to The Critical Role of Diagnostics in COVID-19 Management; MTE VODI working group from 2019 – 2021, where she was part of the core team working on The Value of Diagnostics Information: the case of Heart Failure, VODI in Acute Respiratory Infections – Observations from the COVID-19 pandemic’
Prior to joining the industry, Mikki worked as a postdoctoral research fellow in the field of oncology at the National University of Singapore.
Mikki holds a Msc in Health Economics, Health Policy and Health Management from the London School of Economics and Political Science and a PhD in Biochemistry from the University of Bath, UK.
Sang-Soo (SS) Lee holds a PhD from the Seoul School of Integrated Sciences & Technologies, an MPH (diploma) from the Seoul National University, an MBA from the Helsinki School of Economics and Business Administration and a Bachelors in Genetic Engineering from Sung Kyun Kwan University. He is currently the Senior Director for Health Care Economics and Government Affairs in Medtronic North Asia (Korea and Japan), the head of Center of Expertise (COE), Health Care Economics and Government Affairs, Medtronic APAC, and serves as Chair for KMDIA’s Reimbursement Committee, ISPOR’s Asia Consortium Industry Committee and APACMed’s Market Access Working Group. He also holds the position of Vice Chair for ISPOR Korea Chapter and is a member of the board of directors of the Korean Association of Health Technology Assessment (KAHTA). He also serves as an adjunct professor at the Graduate School for Medical Device Management and Research, Samsung Advanced Institute for Health Science and Technology (SAIHST), and Sung Kyun Kywan University and Graduate Program of Industrial Pharmaceutical Sciences, Yonsei University, Seoul, South Korea.
Anh Bourcet (Nguyen) is a global healthcare leader bringing over 12 years of experience in Asia-Pacific and Europe, in the public (French Safety Agency) and private sectors (Abbott, J&J). She is passionate about making an impact on patient care, by enabling change and better access to innovations. Her various roles in Medical Affairs, Health Economics & Market Access and Regulatory Policy, across diagnostics, medical devices and pharmaceutical industries, enable her to have a broad perspective on different levers of patient access.
Anh Bourcet is currently ASPAC Director, Market Access for Diagnostics in Abbott. In this role, Anh has been leading the Market Access & Policy Shaping strategy for Rapid Diagnostics, while establishing the function. She is Past-Chair of the Asia-Pacific Medical Technology Association Digital Health Committee Reimbursement Working Group, where she led the industry effort in shaping the external environment to drive access for Digital Health Technologies.
Data-driven, she has authored and reviewed many publications and spoken in various scientific and healthcare conferences to advance knowledge & collaboration.
Anh holds a PhD cum laude in Medicinal Chemistry from Paris VI & “Chimie ParisTech” Universities (France), and an Executive Master in Health Industry Management, ESSEC Business School (France).
Academician Datuk Professor Dr Looi Lai Meng is Malaysia’s inaugural National Distinguished Professor (Profesor Ulung), and consultant histopathologist at the University Malaya Medical Centre (UMMC). She co-chaired the InterAcademy Partnership for Health (2010-2016) when this global network of National Sciences and Medical Academies extended initiatives into global health, the social determinants of health, urban health, and young physician leadership capacity-building. She is the Founding President of the Malaysian College of Pathologists and former President of the World Association of Societies of Pathology and Laboratory Medicine, with a specific interest in laboratory accreditation and capacity-building in countries-in-need. She is a Founding Fellow and Senior Fellow (Academician) of the Academy of Sciences Malaysia. Current engagements include the Lancet Commission on Diagnostics, International Regional Advisor (Western Pacific) of the Royal College of Pathologists UK, Vice-President of the World Pathology Foundation, Chair of the UMMC-Medical Research Ethics Committee, MRC (UK) Applied Global Health Research Board and Honorary Professor of the Chinese Academy of Medical Sciences-Peking Union Medical College.
Clinical Associate Prof David Sim is senior consultant and deputy head with the department of cardiology. He is also the director of the heart failure programme and director of clinical and translational research office at the National Heart Centre Singapore (NHCS). He is associate professor at Duke National University of Singapore Graduate Medical School and the current president of the heart failure society (Singapore). His sub-specialty interest is in heart failure, mechanical circulatory support, and heart transplantation. He received a Fellowship in Heart Failure/Heart Transplant at the Alfred Hospital, Melbourne, Australia. He is a member of the committee for adult heart transplant programme in NHCS.
He is the project director for the advanced care planning programme in the NHCS and honorary visiting consultant at dover park hospice. He plays an active role in clinical trials and is the national leader for Singapore for a few key global pharmacological heart failure trials.
In the Asia Pacific region, Prof Sim plays an active role with the setting up of heart failure programme (National Heart Centre of Mongolia and military 175 hospital in Vietnam). He is an international advisor to the Hong Kong heart failure society.
Joanne Yoong is an applied economist working at the intersection of behavioural economics and health and financial decision making for the well-being of vulnerable populations.
Dr Yoong is the founder of Research for Impact, a Singapore-based social enterprise working to make behavioral and social science research accessible, inclusive and transformative for all.
Dr Yoong also holds faculty appointments at the Yong Loo Lin School of Medicine at the National University of Singapore, the London School of Hygiene and Tropical Medicine,Singapore Management University and the RAND Corporation. She is the author of over seventy peer-reviewed articles in leading economics, medical and public health journals.
Dr Yoong serves in various national and international policy and industry advisory capacities. She is currently the Vice President & President Elect of the Singapore chapter of leading professional society for health economics & outcomes research (HEOR)- International Society for Pharamacoeconomics & Outcomes Research (ISPOR). She has previously held positions as the Director of the Center for Health Services and Policy Research at the National University Hospital System, Director of the Asia Pacific Regional Capacity-Building for Health Technology Assessment (ARCH) Initiative, Director of the RAND Behavioural Finance Forum 2012 and founding co-president of the Singapore Health Economics Association. Dr Yoong is also a member of the founding and organizing committee for the first Asian Workshop for Health Economics and Econometrics.
Previously, Dr Yoong was a senior economist & research fellow at the University of Southern California where she directed offices of the USC Centre for Economic & Social Research in Singapore & Washington & was a principal member of the USC Behavioural Economic Studio.
Dr Yoong received her Ph.D. in Economics at Stanford University as an FSI Starr Foundation Fellow after an early career in financial services, and her AB summa cum laude in Economics and Applied and Computational Mathematics from Princeton University.
Joe Caputo has thirty years’ experience in Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR), and is an expert in RWE & HEOR strategy development, market access, health technology assessment, patient-level data analysis, and value communications across multiple continents.
He is the former Associate Director for ESSEC Business School Institute of Health Economics and Management Asia-Pacific, and guest lecturer at ESSEC, former Principal at IMS health where he moved to Singapore in 2012 to set up and manage the Real-World Evidence & HEOR team for the Asia-Pacific region. He also has 14 years of experience at GlaxoSmithKline where his roles included drug development, sales & marketing and global health outcomes.
Anita Song is Director of Health Economics, Policy & Reimbursement, for Medtronic Greater China. Also, Anita is also the Director of Health Industry Branch of China Health Economics Association, and Youth Committee Member of China Health Economics Association. She has rich experiences in policy analysis and advocacy building up communication platforms with different stakeholders, including industry associations, Think Tanks, academy and government organizations. Anita is committed to integrated market access planning and strategy, incorporating registration, tender, HE/HTA and reimbursement and shaping the synergies. Anita gained her MA in the University of Buffalo, the State University of New York, and her MPA from Cornell University.
Bivash CHAKRABORTY – Head – Regulatory Affairs , Quality & Government Affairs – South Asia , working for bioMérieux India Pvt. Ltd for 21+ years based at New Delhi. Post Graduate Diploma in Regulatory Affairs & Lead Auditor for ISO 9001:2015, 13485:2016 & CII Lean Six Sigma Green Belt.
Bivash has a strong background with IVD industry for over 30 + years in various cross functional areas.
Bivash takes part actively with Industry Associations’ to promote IVD related policy advocacies on both regulatory & Government Affairs. Bivash is also represent IVD related issues (Co Chair – FICCI IVD) and represents various working group on IVD& Medical devices (CII & FICCI, NATHEALTH , APACMED).
Christoph Liesche leads Fresenius Medical Care’s regional government and public affairs organization as well as the healthcare systems and policies team in Asia-Pacific and is responsible for the development and execution of respective health care policies, healthcare system analytics as well as pricing & reimbursement related strategies. He joined Fresenius in 2016 as the Strategic Assistant to the regional Management Board member for Asia-Pacific leading regional corporate strategy, investor relations and strategic projects as well as activities related to Management and Supervisory Board of the company.
Prior to joining Fresenius, Christoph Liesche worked in China in the healthcare industry and focused on introducing innovative medical technologies to China. After that, he was engaged with a Management Consulting firm in charge of Client Services and advising German and European companies on their expansion and growth into China and Asia.
In addition, he is an active working group member in various healthcare equipment and market access working groups within the German and European Chamber of Commerce networks throughout Asia. He further is the elected Vice-chair of the government affairs & market access committee of APACMed, the regional medical device association in Asia-Pacific and initiator of the Health Services Working Group within the association.
Christoph Liesche received his Master of International Business from Hult Business School in Shanghai and U.S. and holds a Bachelor Degree in International Economics and Intercultural Business from Heilbronn University, Germany. He speaks five languages.
Dr Saurabh Kumar Global lead for HEOR delivery in IQVIA, including a dedicated team of nearly 25 professionals responsible for delivery of MedTech related projects across the globe. The key deliverables include development of CERs, report writing, and literature reviews across all classes of medical devices. In addition, he leads a group of health economic modelers, who work on developing economic models related to MedTech devices. He has participated as panellist and presenter in DIA MedTech and other MedTech conferences, his key areas of interest have been economic modelling for MedTech, and Digital health.
By background he is an MD, MBA with an experience of nearly 18 years in Healthcare industry.
Anne leads the regional health economics and market access strategy development and execution for the orthopaedic business of Johnson & Johnson MedTech in the region. Liaising with country, regional, and global stakeholders to support country reimbursement and market access strategies, evidence generation, and policy shaping to drive access and adoption of orthopaedic and digital health technologies.
Anne joined Johnson & Johnson Medical in 2005 as an orthopaedic Product Manager, and during this time the Prostheses List (PL) underwent significant reform and found herself managing the transition to the new PL reimbursement model. She was then promoted to Reimbursement Manager and was recognised for her work on shaping the reimbursement of the orthopaedic portfolio. It was during this time that she excelled with Health Technology Assessment submissions and learnt how to leverage real-world evidence for market access and reimbursement requirements.
In 2017, Anne joined the Asia Pacific Health Economic and Market Access Team, responsible for regional market access and evidence generation strategies for the orthopaedic business. Anne also helped shape external HTA policy and assisted cross-functional country and global franchise partners to formulate strategies for new technologies and reimbursement success. In 2019, she was promoted to a global Senior Manager, Health Technology Assessment (HTA) Governance & Excellence role responsible for collaborating with regions and global franchises to maximize transparency, consistency, and developing a best practice approach to HTA related activities.
Dr. Loppow studied chemistry at the University of Hamburg. During his doctor thesis he became head of the Department for Flow Cytometry in the LADR Medical Laboratories of Dr. Kramer in Geesthacht. He switched from lab to administration and became Head of the Marketing Department at LADR Laboratories and ISG Intermed Service. He joined University Medical Center Hamburg-Eppendorf (UKE) 2011 to become Managing Director of the Institute of Pathology and 2012 additionally CEO of the Martini-Klinik. From March 2020 to July 2021 he substituted the Managing Director of the Center for Diagnostics, who was on maternity leave.
Mainly leading strategic policy shaping, industry alliance and cross-functional hospital C-suites platform development, Global Health, HEOR value evidence generation for access improvements, and innovative value access exploration as well. Ning is also taking the co-lead of BD I&D culture development.
Prior to BD, she worked for Johnson & Johnson, Pfizer, taking various roles as field Marketing lead, HEOR lead, access strategy etc. Ning has more than 10 years of experience in healthcare industry.
Ning graduated from Tianjin University with a management master degree. She also completed Mini-MBA training from Central European International Business School (CEIBS).
Prior to joining APACMed, Alicia worked for over 10 years as the Chief Liaison Officer at the China Chamber of Commerce for Import & Export of Medicines and Health Products (CCCMHPIE), one of China’s largest healthcare industry bodies under the Ministry of Commerce. She managed extensive international cooperation network, including with the government and non-government bodies to drive bilateral and multilateral collaboration between China and the emerging markets. She majored in public health at the Vanke School of Public Health of Tsinghua University for her MA degree with a special focus on health technology access, China’s global health strategy, etc.
Zheng Jie, leader of the National Medical Insurance DRG Technical Guidance Group and director of Beijing Medical Insurance Bureau.He believes that the high-quality development of public hospitals is the main direction of medical reform, and hospitals and doctors will determine the success or failure of the reform in the future; and DRG, DIP and other reform measures play a key supporting role.The setting of DRG weights and rates will be the key in determining the allocation of healthcare resources. In the future, health insurance departments and medical institutions will jointly participate in the calculation of weights and the differentiated formulation of premium rates.
Chen Hao, Huazhong University of Science and Technology (HUST), Research Center for Drug Policy and Management, Tongji Medical College; Senior Economist / licensed pharmacist; Deputy Director of HUST Base of National HSA, China; Director of Medical Innovation Research Center, Shanghai Chuangqi Health Development Research Institute; Executive President of Commercial Insurance and Drug Circulation Branch of China Medical Business Association; Standing member of the Medical Security Professional Committee of the Chinese Society of Social Security; Member of China Drug Administration and Research Society; Member of the Supervision and Research Committee on consistency evaluation of generic drugs; Pharmaceutical economics expert of the National Medical Insurance Administration.
Dr. Li Pei is the former Division Director of Health Service of Wuhan Healthcare Administration, China. He received his PhD degree from Peking Union Medical College and worked as doctor-in-charge in the first hospital affiliated to Tsinghua University and Chinese PLA General Hospital respectively. He also has extensive experiences working with non-public hospitals. Since 2015, he has been working as a key member to lead the Center of Hospital Management for CR Medical.
Dr. Wang Haiyin is an associate researcher on health management. He is currently the director of the Health Technology Evaluation and Research Department of the Shanghai Health and Development Research Center, and serves as a youth member of China Health Economics Association. The research directions of Dr. Wang are mainly health technology assessment and health policy research. In the past five years, Dr. Wang has been responsible for and participated in more than 100 projects with NMPA, the National Health Commission, and China Health Economics Association. He is the editor and translator of 4 textbooks, including Health Technology Assessment and Health Technology Assessment in Hospitals.
Dr. Xuan obtained his Ph.D. in Health Economics and Master Degree in Medicine Policy and Market Management from School of Public Health, University of North Carolina at Chapel Hill and completed his medical degree in Shanghai Medical University, China. With more than 20 years of teaching and research experience, Dr. Xuan have published extensively in clinical study, health economic, policy research, market access and outcomes research. He has established extensive professional network with global key opinion leaders and led numerous global policy forums, advisory boards, and government/payer panel discussions. He is current Chair of ISPOR Asia Consortium Advisory Committee. He also has rich experience in researching, teaching, Ph.D. advising and training of government officials, research fellows, and those who focus on the medical and health care service.
Lin Min, Director of the Medical Insurance Office of the Second Affiliated Hospital of Zhejiang University School of Medicine; Master of Hospital Administration (MHA); Chairman of medical Insurance Committee of Zhejiang Medical Association; Member of the Standing Committee of the Medical Insurance Professional Committee of the Chinese Health Economics Association; Member and Youth Committee Deputy Director General of the Medical Insurance Professional Committee of the Chinese Hospital Association; Member of the Medical Insurance Professional Committee of the China National Security Association; Member of the Smart Medical Committee of the World Chinese Medical Doctor Association; Member of the Medical Price Committee of Zhejiang Health Economic Association.
Glenda joins APACMed in September 2021 as Manager, Government Affairs and Market Access Committee. Bringing a public policy perspective to strategic market access topics, Glenda seeks to improve access to care, translate value-based outcomes for reimbursement, and facilitate efficient adoption of innovative medical technologies for patients and populations across the region.
In her career to date, Glenda has worked at the nexus of government, hospitals and research. As a senior policy analyst in Singapore’s health ministry, Glenda participated in developing health and social service reimbursement policy for the intermediate and long-term care sector, as well as led ground hospital operations including implementation of value-based outcomes programme in a tertiary hospital. Most recently, Glenda worked as a Research Associate in a multidisciplinary research team comprising clinicians and research scientists to develop a design-assist device solution for edentulous patients, with the goals of reducing patient wait time and unlocking cost savings through mass customisation.
Glenda holds a masters’ degree from the University of Chicago in social sciences with a concentration in International Political Economy, and an undergraduate degree from LSE in Government and Economics.
Alice Chu is Director of Market Access and Medical Marketing, Asia Pacific, for Glaukos Corporation, a U.S. ophthalmic medical technology and pharmaceutical company focused on transforming the standards of care in treating chronic eye diseases with novel therapies in glaucoma, corneal disorders, and retinal diseases. Her roles include improving patient access to the company’s innovations based on clinical and economic evidence that demonstrate value for money to governments, payers, and hospital administrators, advancing clinical evidence, and educating surgeons in the Asia Pacific region. Prior to Glaukos, Alice was involved in health policy and market access efforts at Boston Scientific and Johnson & Johnson Medical, both at the Southeast Asian and regional levels. She has worked in various healthcare-related enterprises in the United States, such as medical communications and professional education. Alice received her PhD in Molecular and Biochemical Nutrition and Master of Public Health from the University of California, Berkeley. She also holds a Master of Business Administration from Singapore Management University. She is currently the co-president of the UC Berkeley Public Health Alumni Association.
Jane is the Head of Government Affairs & Policy, Asia-Pacific for J&J’s MedTech sector, a newly created role she commenced in early 2021. In this role she coordinates market-based Government Affairs & Policy experts to shape healthcare policy and pricing and reimbursement frameworks to support sustainable healthcare systems in Asia-Pacific.
Prior to this role, Jane headed up the Government Affairs & Policy function for J&J’s Australian and New Zealand business focused on the medtech, pharmaceutical and consumer health sectors. Jane is a member of the APAC Government Affairs & Policy leadership team as well as the J&J MedTech APAC leadership team.
Jane has extensive experience in Government, most notably as a senior adviser to the Australian Prime Minister and has represented Australia during engagements at international forums such as APEC, G20 and the ASEAN Summit.
Before joining the healthcare sector Jane worked in a variety of industries including the energy and logistics industries and the media sector. She has headed up corporate affairs functions for some of Australia’s largest and most iconic companies including Snowy Hydro Limited, Australia Post and public broadcaster SBS.
Jane started her career as a journalist working for News Limited newspapers and spent considerable time in Australian politics working in the Treasury, Communications and IT portfolios before joining the Prime Minister’s office as the Director, Press Office heading a 24/7 media office.
Jane holds a Bachelors’ Degree in Communications from the University of Canberra, Australia and a Masters’ Degree in International Studies from the University of Sydney, Australia.
Jane is based in Singapore.
Belong to Indian Railways Stores Service cadre of 2000 Indian Engineering Services Examination batch. During more than 19 years of professional experience on Indian Railways, has worked on senior roles primarily focussed on procurement and supply chain management. During 2017-2020 was involved in
formulation and implementation of procurement policy for goods on Indian Railways.
Currently involved in procurement policy formulation at the Ministry of Finance.
Graduate in Civil Engineering and have studied law (LL.B.).
Empanelled as an Arbitrator (Executive) with Indian Council of Arbitration.
Ngoc Anh (Julia) Tran is the Chairwoman of Vietnam Center of Excellence for APACMed. She leads the advocacy efforts for medical devices in Vietnam with various Government stakeholders. Her objectives are to build transparent policies across healthcare sector while maintaining the freedom to operate for private sector.
Julia graduated an economics degree from Hanoi Foreign Trade University in Vietnam in 2001. After that, she did her MBA at RMIT University, Australia. Julia has had more than 20 years of working experience in government affairs and management positions in Vietnam, crossing a number of industries from healthcare, mining and biotechnology.
Julia would like to set up a two-way conversation between private sector and Government agencies of Vietnam in the establishment of its policies. She believes that Vietnam can learn and incorporate the best practices in relevant areas into its emerging strategies.
Nathorn (Nui) Chaiyakunapruk is currently a Professor in the Department of Pharmacotherapy at the University of Utah College of Pharmacy in Salt Lake City. He earned a Doctorate of Pharmacy (PharmD) from the University of Wisconsin-Madison, and his PhD in Pharmaceutical Outcomes Research and Policy Program from the University of Washington.
His expertise is in Health Technology Assessment. He has applied several HTA methodologies (Health Economics, Real World Data Analysis, and Evidence Synthesis: systematic review and classical/network meta-analysis) to support national and global policy, especially his contributions to the World Health Organization. His
research is in broad areas ranging from infectious diseases, non-communicable diseases, community pharmacy, immunization program, complementary and alternative medicines, pharmacogenomics, and smoking cessation. His recent projects have been focused on snakebite burden, cannabis, fatty liver, anticoagulation, and Alzheimer disease.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.
WE HELP MAKE THE WORLD A HEALTHIER PLACE
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide.
We develop and produce diagnostic solutions that help healthcare professionals quickly and reliably determine a pathology or the source of a contamination, and provide them with crucial information for optimal patient care.
Our high-performance solutions are based on three key areas of in vitro diagnostics – Microbiology, Immunoassays and Molecular biology.
Philips is a leading health technology company focused on improving people’s lives across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that address the Quadruple Aim: improved patient experience, better health outcomes, improved staff experience, and lower cost of care. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.
Roche established a presence in the Asia Pacific in 1925. Today, we operate in 16 locations across the Asia Pacific region from Pakistan to Australia and New Zealand, supported by more than 5,700 employees. With the industry’s most comprehensive diagnostics portfolio, we are committed to innovate diagnostics, shaping healthcare and changing lives. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
Sponsors receive the exclusive opportunity to physically attend the Symposiums at our event venue.
For sponsorship opportunities, please contact Gabriel Sim.
IQVIA is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, dedicated to creating intelligent connections that deliver unique innovations and actionable insights. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients.
With regional headquarters in Singapore and offices in 15 countries, IQVIA Asia Pacific provides technology-enabled services and solutions to meet the growing and rapidly changing needs of clients, both local and multinational.
BROUGHT TO YOU BY